Tag Archives: Actinium Pharmaceuticals

Actinium Pharmaceuticals (ATNM) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) on January 13 and set a price target of $65.00. The company’s shares closed last Tuesday at $8.06. According to TipRanks.com, Pantginis is a

Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (NYSE MKT: ATNM) and Codiak BioSciences (NASDAQ: CDAK)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Actinium Pharmaceuticals (ATNM – Research Report) and Codiak BioSciences (CDAK – Research Report) with bullish sentiments. Actinium Pharmaceuticals (ATNM) William Blair analyst

Actinium Pharmaceuticals (ATNM) Receives a Buy from H.C. Wainwright

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), with a price target of $65.00. The company’s shares closed last Friday at $10.84. According to TipRanks.com, Pantginis is

Actinium Pharmaceuticals (ATNM) Gets a Buy Rating from William Blair

In a report issued on November 4, Andy Hsieh from William Blair reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report). The company’s shares closed last Thursday at $10.40. According to TipRanks.com, Hsieh is a 4-star analyst with

Maxim Group Keeps Their Buy Rating on Actinium Pharmaceuticals (ATNM)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report). The company’s shares closed last Friday at $9.28. According to TipRanks.com, McCarthy is a 5-star analyst with an average

William Blair Keeps Their Buy Rating on Actinium Pharmaceuticals (ATNM)

William Blair analyst Andy Hsieh reiterated a Buy rating on Actinium Pharmaceuticals (NYSE MKT: ATNM) on May 13. Actinium Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $2.75, representing a 1209.5% upside. In a